DNA repair genes implicated in triple negative familial non-BRCA1/2 breast cancer predisposition.

Among breast cancers, 10 to 15% of cases would be due to hereditary risk. In these familial cases, mutations in BRCA1 and BRCA2 are found in only 15% to 20%, meaning that new susceptibility genes remain to be found. Triple-negative breast cancers represent 15% of all breast cancers, and are generally aggressive tumours without targeted therapies available. Our hypothesis is that some patients with triple negative breast cancer could share a genetic susceptibility different from other types of breast cancers. We screened 36 candidate genes, using pyrosequencing, in all the 50 triple negative breast cancer patients with familial history of cancer but no BRCA1 or BRCA2 mutation of a population of 3000 families who had consulted for a familial breast cancer between 2005 and 2013. Any mutations were also sequenced in available relatives of cases. Protein expression and loss of heterozygosity were explored in tumours. Seven deleterious mutations in 6 different genes (RAD51D, MRE11A, CHEK2, MLH1, MSH6, PALB2) were observed in one patient each, except the RAD51D mutation found in two cases. Loss of heterozygosity in the tumour was found for 2 of the 7 mutations. Protein expression was absent in tumour tissue for 5 mutations. Taking into consideration a specific subtype of tumour has revealed susceptibility genes, most of them in the homologous recombination DNA repair pathway. This may provide new possibilities for targeted therapies, along with better screening and care of patients.

[1]  Gladys Ibanez,et al.  Variants in DNA double-strand break repair genes and risk of familial breast cancer in a South American population , 2010, Breast Cancer Research and Treatment.

[2]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[3]  J. Thigpen.  Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer , 2011 .

[4]  Pilar Zamora,et al.  The variant E233G of the RAD51D gene could be a low‐penetrance allele in high‐risk breast cancer families without BRCA1/2 mutations , 2004, International journal of cancer.

[5]  R. Scott,et al.  Low prevalence of germline PALB2 mutations in Australian triple‐negative breast cancer , 2014, International journal of cancer.

[6]  Yair Andegeko,et al.  Requirement of the MRN complex for ATM activation by DNA damage , 2003, The EMBO journal.

[7]  H. Perdry,et al.  [A new scoring system for the diagnosis of BRCA1/2 associated breast-ovarian cancer predisposition]. , 2011, Bulletin du cancer.

[8]  A. Wilkinson,et al.  AAA+ superfamily ATPases: common structure–diverse function , 2001, Genes to cells : devoted to molecular & cellular mechanisms.

[9]  Y. Bignon,et al.  CHEK2 contribution to hereditary breast cancer in non-BRCA families , 2011, Breast Cancer Research.

[10]  Karla Bowles,et al.  Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next‐generation sequencing with a 25‐gene panel , 2015, Cancer.

[11]  R. Schwab,et al.  Breast cancer in a RAD51D mutation carrier: case report and review of the literature. , 2015, Clinical breast cancer.

[12]  A. Sokolenko,et al.  Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele , 2014, Medical Oncology.

[13]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  C. Amos,et al.  Cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital based Lynch syndrome registry , 2012, Familial Cancer.

[15]  A. Sidow,et al.  Physicochemical constraint violation by missense substitutions mediates impairment of protein function and disease severity. , 2005, Genome research.

[16]  O. Ohara,et al.  Two brothers with ataxia-telangiectasia-like disorder with lung adenocarcinoma. , 2009, The Journal of pediatrics.

[17]  J. Stockman.  Cancer Risks Associated With Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch Syndrome , 2013 .

[18]  S. Seal,et al.  BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years , 2012, British Journal of Cancer.

[19]  Mitchell H. Gail,et al.  Power Computations for Designing Comparative Poisson Trials , 1974 .

[20]  J. Hopper,et al.  Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study , 2014, Breast Cancer Research.

[21]  L. Norton,et al.  DNA Mismatch Repair Deficiency in Breast Carcinoma: A Pilot Study of Triple-negative and Non–Triple-negative Tumors , 2012, The American journal of surgical pathology.

[22]  D. Eccles,et al.  Analysis of RAD51D in Ovarian Cancer Patients and Families with a History of Ovarian or Breast Cancer , 2013, PloS one.

[23]  N. Kyrpides,et al.  Direct Comparisons of Illumina vs. Roche 454 Sequencing Technologies on the Same Microbial Community DNA Sample , 2012, PloS one.

[24]  Daniel J. Park,et al.  19p13.1 is a triple-negative-specific breast cancer susceptibility locus. , 2012, Cancer research.

[25]  D. Pittman,et al.  Cisplatin resistance conferred by the RAD51D (E233G) genetic variant is dependent upon p53 status in human breast carcinoma cell lines , 2009, Molecular carcinogenesis.

[26]  H. Nevanlinna,et al.  Aberrations of the MRE11–RAD50–NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer‐predisposing gene , 2008, Molecular oncology.

[27]  The Polish Breast Cancer Consortium.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002 .

[28]  S. Plon.  The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype , 2010 .

[29]  C. Béroud,et al.  Human Splicing Finder: an online bioinformatics tool to predict splicing signals , 2009, Nucleic acids research.

[30]  Y. Bignon,et al.  Evaluation of Breast Cancer Risk in a Multigenic Model Including Low Penetrance Genes Involved in Xenobiotic and Estrogen Metabolisms , 2010, Nutrition and cancer.

[31]  G. Mills,et al.  Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer , 2011, Clinical Cancer Research.

[32]  Bing Xia,et al.  PALB2/FANCN: recombining cancer and Fanconi anemia. , 2010, Cancer research.

[33]  D. Pittman,et al.  Extensive chromosomal instability in Rad51d-deficient mouse cells. , 2005, Cancer research.

[34]  Changanamkandath Rajesh,et al.  Functional characterization of the RAD51D E233G genetic variant , 2009, Pharmacogenetics and genomics.

[35]  K. Manova-Todorova,et al.  The Mre11 complex suppresses oncogene-driven breast tumorigenesis and metastasis. , 2013, Molecular cell.

[36]  W. Willett,et al.  Genetic variation in DNA repair pathway genes and premenopausal breast cancer risk , 2009, Breast Cancer Research and Treatment.

[37]  S. Salzberg,et al.  GeneSplicer: a new computational method for splice site prediction. , 2001, Nucleic acids research.

[38]  Ping Sun,et al.  CHEK2 mutations and the risk of papillary thyroid cancer , 2015, International journal of cancer.

[39]  Yongchao Liu,et al.  HECTOR: a parallel multistage homopolymer spectrum based error corrector for 454 sequencing data , 2014, BMC Bioinformatics.

[40]  I. Adzhubei,et al.  Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2 , 2013, Current protocols in human genetics.

[41]  S. Aparicio,et al.  The omics of triple-negative breast cancers. , 2014, Clinical chemistry.

[42]  A. Børresen-Dale,et al.  BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations , 2010, BMC Cancer.

[43]  R. Winqvist,et al.  Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility , 2003, Journal of medical genetics.

[44]  Brigitte Rack,et al.  Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Dąbrowska,et al.  A novel germline PALB2 deletion in Polish breast and ovarian cancer patients , 2010, BMC Medical Genetics.

[46]  J. Benítez,et al.  The complex genetic landscape of familial breast cancer , 2013, Human Genetics.

[47]  T. Dörk,et al.  Human RAD50 deficiency in a Nijmegen breakage syndrome-like disorder. , 2009, American journal of human genetics.

[48]  Nazneen Rahman,et al.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles , 2006, Nature Genetics.

[49]  Daniel J. Park,et al.  Tumour morphology predicts PALB2 germline mutation status , 2013, British Journal of Cancer.

[50]  S. West,et al.  Telomere Maintenance Requires the RAD51D Recombination/Repair Protein , 2004, Cell.

[51]  Junjie Chen,et al.  PALB2 is an integral component of the BRCA complex required for homologous recombination repair , 2009, Proceedings of the National Academy of Sciences.

[52]  G. Giles,et al.  After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer. , 2001, American journal of human genetics.

[53]  Daniel J. Park,et al.  Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families , 2013, Breast Cancer Research.

[54]  Feng Zhang,et al.  PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response , 2009, Current Biology.

[55]  Deborah Hughes,et al.  Germline mutations in RAD51D confer susceptibility to ovarian cancer , 2011, Nature Genetics.

[56]  Nazneen Rahman,et al.  ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles , 2006, Nature Genetics.